1. Medtech Insight
  2. >>Policy & Regulation

Greater Transparency For Medicare Advantage Program Needed, MDMA Says

 
• By Hannah Daniel

Medtech industry groups call for greater transparency and oversight for Medicare Advantage plans.

• Source: Shutterstock

The US government needs to provide more transparency for industry and payers into its oversight of Medicare Advantage (MA) programs, the Medical Device Manufacturers Association (MDMA) said.

In a 13 February letter to the Center for Medicare and Medicaid Services (CMS) Administrator, MDMA expressed its concerns...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

Remote Regulatory Assessments Become Swiss Army Knife For US FDA’s Oversight Of Facilities

 
• By Malcolm Spicer

“RRAs are valuable oversight tools and under certain circumstances, can assist FDA in its mission to protect public health, oversee regulated industry, and help ensure regulated products comply with FDA requirements,” according to final guidance.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 
• By Brian Bossetta

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, home of Medtech Insight, to focus on AI, business harmonization and long-term growth.